

The Association of miR-451 and miR-21 in Plasma with Lymph Node Metastases in Breast Cancer

M. Motamedi (MSc)¹, M. Hashemzadeh Chaleshtori (PhD)¹, S. Ghasemi (PhD) *¹,
S. Kheiri (PhD)², A. Haji Gholami (MD)³

1.Cellular and Molecular Biology Research Center, Basic Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, I.R.Iran

2.Department of Biostatistics and Epidemiology, Faculty of Public Health, Shahrekord University of Medical Sciences, Shahrekord, I.R.Iran

3.Faculty of Medicine, Isfahan University of Medical Sciences, I.R.Iran

J Babol Univ Med Sci; 20(4); Apr 2018; PP: 12-16

Received: Sep 3rd 2017, Revised: Dec 2nd 2017, Accepted: Dec 25th 2017.

ABSTRACT

BACKGROUND AND OBJECTIVE: The expression of some circulating microRNAs (miRNAs) in biological fluids of healthy individuals is different from cancerous patients. circulating miRNAs are a new class of cancer biomarkers because of their high stability and sensitivity, ease of measurement and specificity due to their correlation with various cancer states. According to the miR-451 and miR-21 functions in the metastasis of some cancers, the aim of this study was to investigate the differences of expression levels of miR-451 and miR-21 in the plasma of breast cancer (BC) patients with and without lymph nodes metastasis (LNM).

METHODS: In this descriptive-analytical study, blood samples were collected from 47 women with BC and 24 healthy women with mammography confirmation. The presence/or absence of LNM was recognized from patients' medical records. The expression levels of miR-451 and miR-21 in the plasma, were investigated using Real-Time PCR.

FINDINGS: The median of expression of miR-451 in BC patients with LNM and without LNM was 1.739 and 3.187, respectively, and its expression in lymph node metastatic patients decreased 0.444 folds in comparison with non-metastatic patients (p=0.031). The median of expression of miR-21 in patients with LNM and in non-metastatic lymph nodes patients was 5.922 and 2.157, respectively, and its expression in metastatic status was 2 folds higher than non-metastatic (p=0.029).

CONCLUSION: The results of this study indicated that decreased miR-451 and increased miR-21 expression in plasma of BC patients was associated with LNM status.

KEY WORD: *Breast Cancer, Lymph Node Metastasis, miR-451, miR-21.*

Please cite this article as follows:

Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Kheiri S, Haji Gholami A. The Association of miR-451 and miR-21 in Plasma with Lymph Node Metastases in Breast Cancer. J Babol Univ Med Sci. 2018;20(4):12-16.

*Corresponding Author: S. Ghasemi (PhD)

Address: Cellular-Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, I.R.Iran.

Tel: +98 38 33331471

E-mail: sorayya.ghasemi@gmail.com

Introduction

Breast cancer is the most common type of cancer in women. Recurrence and metastasis are the main causes of death from this cancer (1). The status of metastasis to lymph nodes is one of the most important prognostic factors in breast cancer and it is important in clinical decision-making, proper surgical selection and treatment outcomes (2). This parameter is a measure of the survival status of patients (3). Most conventional diagnostic methods and biomarkers in breast cancer are not able to detect metastatic lymph nodes, and accepted methods such as lymphatic mapping and biopsy of lymph nodes can not be applied to all patients (4).

Therefore, the identification of noninvasive biomarkers is important for tracking lymph node metastases. miRNAs are a type of non-coding RNAs. Exposure profiles of microRNAs have high potential for specific detection of different cancers, as well as pathologic stages and pathologies different from one type of cancer (5). In breast cancer, miR-451 and miR-21 expressions are dysregulated in tumor cells and some biological fluids such as plasma (7, 6). In many studies, the role of miR-21 as a key onco miR has been identified that increasing the expression of miR-21 in tumor tissue is associated with the onset, progression or metastasis of some cancers (8, 1).

On the other hand, miR-451 is a tumor suppressant. Consequently, the reduction of the expression of this miRNA plays a role in breast cancer (9). Considering the importance of the status of lymph node metastases for better management of breast cancer in order to use the appropriate treatment protocol (2) and considering the role of miR-451 and miR-21 in metastasis (9), in the present study for the first time non-invasive analysis of the possible changes in the level of expression of these two miRNAs in the blood plasma of patients with breast cancer in relation to the status of metastatic lymph nodes compared to healthy subjects. By continuing this study in the future, it might be possible to use two miRNAs as noninvasive biomarkers to detect breast cancer metastasis to lymph nodes.

Methods

In this descriptive-analytical study, after approval by the ethics committee of Shahrekord University of Medical Sciences (Registration code: IR.SKUMS.REC.1394.178), peripheral blood of 47

women with breast cancer and 24 healthy women were collected. Women with all four stages of breast cancer and ductal carcinoma were included in the study. Healthy people were selected with a mean age similar to women with breast cancer who had been mammographed during the sampling period and their health was confirmed. Confirmation of the health or illness of the women studied by examining or considering a mammogram report by an oncologist (10). Samples were collected from Isfahan and Shahr-e-Kord Hospitals, after obtaining written consent and during 18 months, from 2015 to 2016.

Clinical information such as the stage of cancer, the presence or absence of metastasis to the lymph nodes after surgery, and the sending of mass samples to the laboratory were determined by the pathologist. Blood plasma was isolated from other parts by blood centrifuge in 7 minutes and with 2500 rpm. The expression of miR-451 and miR-21 variables in two groups of breast cancer patients (eligible/without metastasis of lymph nodes) were evaluated using Real-Time PCR.

From 250 µl of plasma samples, miRNAs were extracted using a kit (exiqon, 300112). Subsequently, cDNA synthesis was performed using kits (00101005, Pars Genome) and based on the company protocol. Real-Time PCR reaction was performed using SYBRGreen (RRS20Q, Takara) and miR-451, miR-21 specific primers and internal control gene U6snRNA (00101007, Pars Genome).

The Real-Time PCR reaction was performed with three repetitions for each sample. Expression ratios for miR-21 and miR-451 in plasma of patients were calculated by the $\Delta\Delta C_t$ -2 formula in $\Delta C_t = C_{t\text{interested miRNA}} - C_{tU6snRNA}$ and $\Delta\Delta C_t = \Delta C_{t\text{sample (patient)}} - \Delta C_{t\text{control}}$. Data analysis was performed using SPSS software version 18 (SPSS Inc., Chicago, Ill., USA) and the analysis of variance and Fisher's exact test were used for comparison between the two groups and the non-parametric Mann-Whitney U test was used for comparison of expression changes and $p < 0.05$ was considered significant.

Results

Variables: Clinopathological profile: The mean age of healthy and ill women were 45.6 ± 14.3 and 49.6 ± 10 years, respectively. Out of 47 women with breast cancer, 29 had metastasis to lymph nodes (Table 1). The association of miR-451 expression in plasma with

metastasis of lymph nodes: The mean ratio of expression of miR-451 in breast cancer patients with lymph node metastases and no lymph node metastasis was 1.73 and 3.871, respectively. Therefore, the expression of miR-451 in the plasma of metastatic patients decreased by 0.444 ($p=0.031$) compared to non-metastatic patients (Fig.1A). The association of miR-451 expression in plasma with other clinical features: changes in the expression of miR-451 in

relation to the status of ER, PR, Her2 and the stage of breast cancer were not significant ($p=0.682$, $p=0.973$, $p=0.823$ and $p=0.344$). The association of miR-21 expression in plasma with metastasis in the lymph nodes: The mean ratio of miR-21 expression in patients with metastatic lymph nodes and in patients without metastasis were 5.92 and 5.157, respectively. The expression of miR-21 in metastatic state was 2 times higher than non-metastasis ($p=0.029$) (Fig. 1B).

Table 1. Clinopathological profile of patients: The number of each patient is shown in terms of the variables studied

Variable	Level of variable	Number of patients
Stage	one	2
	Two	17
	three	4
	four	3
ER Receptor	positive	18
	negative	5
PR Receptor	positive	16
	negative	7
Her2/nu Receptor	positive	5
	negative	18
Lymph node metastases	positive	29
	negative	18




Figure 1. MiR-451 and miR-21 expression patterns associated with metastasis of lymph nodes in breast cancer: (a) related to changes in the expression of miR-451; and (b) miR-21 expression changes. The level of expression of these two microRNAs in comparison with the absence of metastasis was decreased 0.442 fold ($p = 0.031$) and increased 2 times, respectively ($p=0.029$).

Discussion

In this study, changes in plasma miR-451 and miR-21 plasma expression in patients with breast cancer, with regard to the status of metastasis to lymph nodes, were significantly altered in these patients. Identification of lymph node metastases plays a very

important role in the treatment of breast cancer and plays a role in the choice of surgical procedure and subsequent therapeutic treatment (4). Previous studies have shown that miR-451 plays a role in tumor suppression in various cancers. Pan et al. showed that most of the target genes of the miRNA, such as c-Myc,

RAB14 and others, are oncogene and play a role in tumorigenesis and metastatic pathways. Obviously, the results of many studies on various cancers indicate a reduction in the expression of miR-451 in tumor cells (11). The results showed that the plasma expression of miR-451 is reduced in relation to breast cancer metastasis. Bandres et al showed that a lower expression of miR-451 is associated with a lower survival of gastric cancer patients (12).

Another study by Wang et al. on lung cancer revealed a reduction in the expression of miR-451 with more advanced stages, metastasis to lymph nodes, and tumor differentiation (13). Plasma miR-21 plasma concentrations were higher in patients with metastatic lymph nodes than in patients without lymph node metastasis. This finding is also consistent with some similar studies in this area. Yan and colleagues compared the breast tumor tissue with healthy surrounding tissues and it was found that increased and elevated expression of miR-21 was associated with more advanced stages of cancer and metastases to lymph nodes (14).

In a study by Ota et al. on bone marrow tissue in breast cancer patients, individuals with metastatic lymph nodes had a higher expression of miR-21 than non-metastatic patients (15). Due to the higher value of noninvasive studies than biopsy, in the present study, the use of plasma versus tissue samples has been used in previous studies. The results suggest that expression of miR-21 increases when disease progresses, and especially during metastases. Melnik et al showed that miR-21 is a key onco miR, and in many cancers, the level of its expression is elevated. Maintaining the proliferation signal, escape from growth inhibitors, activating invasion and metastasis, inducing angiogenesis and oxidative stress, as well as genetic

instability are some of its roles (16). Zhu et al. showed that PDCD4 (programmed cell death protein) and Maspin are miR-21 targets that reduce the potential for invasion and metastasis in breast cancer. Thus, miR-21 is important for tumor cell invasion by targeting metastasis inhibitors (17). In general, these studies can explain the link between increased expression of miR-21 and a greater reduction in the expression of miR-451 in parallel with the presence of metastasis to lymph nodes. It can be concluded that with significant changes in the level of expression of miR-451 and miR-21 in relation to metastasis of lymph nodes in breast cancer patients, and on the other hand, due to changes in expression in plasma of patients that compared with tissue samples in the previous studies is less invasive, so it may be possible to use these two miRs in determining the prognosis of the metastasis and, consequently, the determination of therapeutic approaches.

Suggestions: In order to confirm the correlation between the clinical features of breast cancer with changes in the expression of miR-451 and miR-21 in the plasma of patients and their use as prognostic biomarkers in breast cancer, it is suggested a study with more sample size in this regard.

Conflict of Interest: No conflicts of interest.

Acknowledgment

Hereby, we would like to thank from the officials of the Cellular and Molecular Sciences Research Center of Shahrekord University of Medical Sciences, and also from Dr. Fariborz Makarian and Dr. Mohammad Amiri for their cooperation.

References

- 1.Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in iran. *Ir J Pub Health*. 2015;44(3):430-1.
- 2.Cote R, Fpeterston H, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. *Lancet*. 1999;354(9182):896-900.
- 3.Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer*. 1989;63(1):181-7.
- 4.Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. *Tumor Biol*. 2013;34(1):455-62.
- 5.Makarova JA, Shkurnikov MU, Wicklein D, Lange T, Samatov TR, Turchinovich AA, et al. Intracellular and extracellular microRNA: An update on localization and biological role. *Progs Histochem Cytochem*. 2016;20(3):282-302.
- 6.Erbes T, Hirschfeld M, Rücker G, Jaeger M, Boas J, Iborra S, et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. *BMC Cancer*. 2015;15(1):193.
- 7.Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. *PloS One*. 2013;8(1):53141.
- 8.Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. *Ann Lab Med*. 2015;35(2):226-32.
- 9.Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3 ζ and promotes breast cancer cell survival and endocrine resistance. *Oncogene*. 2012;31(1):39-47.
- 10.Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, et al. Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: Cancer J Clin*. 2015;65(1):30-54.
- 11.Pan X, Wang R, Wang Z-X. The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. *Mol Cancer Ther*. 2013;12(7):1153-62.
- 12.Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. *Clin Cancer Res*. 2009;15(7):2281-90.
- 13.Wang R, Wang Z, Yang J, Pan X, De W, Chen L. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). *Oncogene*. 2011; 30(23): 2644.
- 14.Yan L-X, Huang X-F, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *Rna*. 2008; 14(11): 2348-60.
- 15.Ota D, Mimori K, Yokobori T, Uchi R, Hirata H, Hisateru Komatsuet al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. *Inter J Oncol*. 2011;38(4):955.
- 16.Melnik BC. MiR-21: an environmental driver of malignant melanoma?. *J Translat Med*. 2015;13(1):202.
- 17.Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. *Biochem Pharmacol*. 2008;76(5):582-8.